observed between daily symptoms and daily assessments of activity function items (r=0.66-0.77), feeling tired (r=0.66-0.76), and ACQ-6 scores (r=0.58-0.68) at baseline and change from baseline to end of treatment. Moderate correlations were observed between symptom scores and feeling stressed (r=0.36-0.50); rescue medication use (r=0.49-0.57); and AQLQ(S)+12 overall and symptoms, activity limitation, and emotional domains (r=À0.41-0.62). Although a very weak correlation between symptom improvement and FEV 1 was expected, benralizumab-treated patients had a better correlation between symptom improvement and FEV 1 improvement compared with placebo (r=À0.21 vs. À0.13), possibly because of substantial FEV 1 improvement observed in benralizumabtreated patients. Conclusions Asthma-related symptoms and improvements are associated with other important aspects of improvement in patient well-being, especially for patients uncontrolled on optimal care.
P69
FUNCTIONALITY, RELIABILITY, AND PERFORMANCE OF AN ACCESSORISED PRE-FILLED SYRINGE WITH HOME-ADMINISTERED SUBCUTANEOUS BENRALIZUMAB FOR ADULT PATIENTS WITH SEVERE ASTHMA Introduction and Objectives Benralizumab, a humanised antieosinophil monoclonal antibody, is in development as an addon treatment for severe, uncontrolled, eosinophilic asthma. During Phase III trials, benralizumab significantly reduced annual asthma exacerbation rates and was well-tolerated.
1,2
The GREGALE study (NCT02417961) assessed patient and caregiver-reported functionality, performance, and reliability of an accessorised pre-filled syringe (APFS) used to administer benralizumab subcutaneously in an at-home setting. Methods Patients (n=116) with severe, uncontrolled asthma despite receiving medium-or high-dosage inhaled corticosteroids and long-acting b 2 -agonists, received up to five APFSadministered subcutaneous doses (Weeks 0, 4, 8, 12, and 16) of 30 mg benralizumab. The first three doses were administered at the study sites. The patient/caregiver administered the last two doses at home. Endpoints included the percentage of patients/caregivers who successfully administered benralizumab at home, percentage of APFS returned to study sites and eval- . Incidence of adverse events leading to benralizumab discontinuation was 2.6%. Most common adverse events (!5% of patients) were nasopharyngitis, upper respiratory tract infection, headache, and sinusitis. Five patients (4.3%) experienced transient mild or moderate injectionsite reactions. Conclusions Most patients and caregivers successfully administered benralizumab in an at-home setting. The APFS was functional, reliable, and performed well.
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